Mariana Faucz Munhoz da Cunha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mariana Faucz Munhoz da Cunha has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Fellype Carvalho Barreto
Universidade Federal do Paraná
5 shared publications - Aline Grosskopf Monich
Departamento de Clínica Médica, Programa de Pós-Graduação em Medicina Interna e Ciências da Saúde, Universidade Federal do Paraná, Curitiba, Brazil
3 shared publications - Adriana Koliski
Pediatric Intensive Care Unit, Complexo Hospital de Clínicas da Universidade Federal do Paraná, Brazil
1 shared publication - Adriana Mello Rodrigues
Hospital Pequeno Príncipe – Curitiba (PR), Brazil|Universidade Federal do Paraná – Hospital de Clínicas – Curitiba (PR), Brazil
1 shared publication - Andrei Odevar Cêa
Universidade Federal do Paraná, Curitiba, Brazil
1 shared publication - Carmem Bonfim
Duke University – Durham – Carolina do Norte – Estados Unidos
1 shared publication
Latest Publications
- Open Access
- 9 July 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Features and management of kidney manifestations of tuberous sclerosis complex: a real-world study in a Brazilian patient cohort
Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder resulting from pathogenic variants in the TSC1 or TSC2 genes, leading to hyperactiva
- 9 July 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Open AccessFeatures and management of kidney manifestations of tuberous sclerosis complex: a real-world study in a Brazilian patient cohort
Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder resulting from pathogenic variants in the TSC1 or TSC2 genes, leading to hyperactiva
- Open Access
- 1 December 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (4) , 503-505
Inibidores da mTOR são a primeira escolha no tratamento de angiomiolipomas renais associados à esclerose tuberosa
Lemos com grande interesse o relato de caso “Tratamento endovascular de sangramentos e angiomiolipomas de aneurismas intrarrenais em um paciente com esclerose tuberosa e doença renal policística” de Leite et al.1 1. Leite T, Pazinato LV, Vidal MJA, Freitas D, Leal Fo JMM. Endovascular treatment of intrarenal aneurysms bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease. J Bras Nefrol. 2023;45(1):111–5. doi: http://dx.doi.org/10.1590/2175-8239-jbn-2021-0023. PubMed PMID: 34328493. https://doi.org/10.1590/2175-8239-jbn-20... , os quais reportam o sucesso terapêutico da embolização. Esse tratamento intervencionista preemptivo e curativo, nos casos de hemorragias, é preferencial às nefrectomias, tanto parciais quanto totais, para preservar o parênquima e a função renais2 2. Williams JM, Racadio JM, Johnson ND, Donnelly LF, Bissler JJ. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis. 2006;47(1):95–102. doi: http://dx.doi.org/10.1053/j.ajkd.2005.09.028. PubMed PMID: 16377390. https://doi.org/10.1053/j.ajkd.2005.09.0... . Porém, vale ressaltar que, atualmente, o tratamento preemptivo de primeira escolha angiomiolipomas renais secundários à esclerose tuberosa é o medicamentoso, com inibidores da mTOR (imTOR), e não a embolização3 3. Bissler JJ, Christopher Kingswood J. Renal manifestation of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):338–47. doi: http://dx.doi.org/10.1002/ajmg.c.31654. PubMed PMID: 30307110. https://doi.org/10.1002/ajmg.c.31654... ,4 4. Li M, Zhou Y, Chen C, Yang T, Zhou S, Chen S, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019;14(1):39. doi: http://dx.doi.org/10.1186/s13023-019-1012-x. PubMed PMID: 30760308. https://doi.org/10.1186/s13023-019-1012-... .
- 1 December 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (4) , 503-505
Open AccessInibidores da mTOR são a primeira escolha no tratamento de angiomiolipomas renais associados à esclerose tuberosa
Lemos com grande interesse o relato de caso “Tratamento endovascular de sangramentos e angiomiolipomas de aneurismas intrarrenais em um paciente com esclerose tuberosa e doença renal policística” de Leite et al.1 1. Leite T, Pazinato LV, Vidal MJA, Freitas D, Leal Fo JMM. Endovascular treatment of intrarenal aneurysms bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease. J Bras Nefrol. 2023;45(1):111–5. doi: http://dx.doi.org/10.1590/2175-8239-jbn-2021-0023. PubMed PMID: 34328493. https://doi.org/10.1590/2175-8239-jbn-20... , os quais reportam o sucesso terapêutico da embolização. Esse tratamento intervencionista preemptivo e curativo, nos casos de hemorragias, é preferencial às nefrectomias, tanto parciais quanto totais, para preservar o parênquima e a função renais2 2. Williams JM, Racadio JM, Johnson ND, Donnelly LF, Bissler JJ. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis. 2006;47(1):95–102. doi: http://dx.doi.org/10.1053/j.ajkd.2005.09.028. PubMed PMID: 16377390. https://doi.org/10.1053/j.ajkd.2005.09.0... . Porém, vale ressaltar que, atualmente, o tratamento preemptivo de primeira escolha angiomiolipomas renais secundários à esclerose tuberosa é o medicamentoso, com inibidores da mTOR (imTOR), e não a embolização3 3. Bissler JJ, Christopher Kingswood J. Renal manifestation of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):338–47. doi: http://dx.doi.org/10.1002/ajmg.c.31654. PubMed PMID: 30307110. https://doi.org/10.1002/ajmg.c.31654... ,4 4. Li M, Zhou Y, Chen C, Yang T, Zhou S, Chen S, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019;14(1):39. doi: http://dx.doi.org/10.1186/s13023-019-1012-x. PubMed PMID: 30760308. https://doi.org/10.1186/s13023-019-1012-... .
- Open Access
- 1 December 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (4) , 503-505
mTOR inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis
We read with great interest the case report “Endovascular treatment of intrarenal aneurysm bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease” by Leite et al.1 1. Leite T, Pazinato LV, Vidal MJA, Freitas D, Leal Fo JMM. Endovascular treatment of intrarenal aneurysms bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease. J Bras Nefrol. 2023;45(1):111–5. doi: http://dx.doi.org/10.1590/2175-8239-jbn-2021-0023. PubMed PMID: 34328493. https://doi.org/10.1590/2175-8239-jbn-20... , in which embolization was successfully employed. In cases of bleeding, this preemptive interventional and curative treatment is preferable to partial or total nephrectomy, since it preserves the renal parenchyma and kidney function2 2. Williams JM, Racadio JM, Johnson ND, Donnelly LF, Bissler JJ. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis. 2006;47(1):95–102. doi: http://dx.doi.org/10.1053/j.ajkd.2005.09.028. PubMed PMID: 16377390. https://doi.org/10.1053/j.ajkd.2005.09.0... . Currently, however, the preemptive treatment of choice for tuberous sclerosis-related angiomyolipomas is mTOR inhibitors, not embolization3 3. Bissler JJ, Christopher Kingswood J. Renal manifestation of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):338–47. doi: http://dx.doi.org/10.1002/ajmg.c.31654. PubMed PMID: 30307110. https://doi.org/10.1002/ajmg.c.31654... ,4 4. Li M, Zhou Y, Chen C, Yang T, Zhou S, Chen S, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019;14(1):39. doi: http://dx.doi.org/10.1186/s13023-019-1012-x. PubMed PMID: 30760308. https://doi.org/10.1186/s13023-019-1012-... .
- 1 December 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (4) , 503-505
Open AccessmTOR inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis
We read with great interest the case report “Endovascular treatment of intrarenal aneurysm bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease” by Leite et al.1 1. Leite T, Pazinato LV, Vidal MJA, Freitas D, Leal Fo JMM. Endovascular treatment of intrarenal aneurysms bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease. J Bras Nefrol. 2023;45(1):111–5. doi: http://dx.doi.org/10.1590/2175-8239-jbn-2021-0023. PubMed PMID: 34328493. https://doi.org/10.1590/2175-8239-jbn-20... , in which embolization was successfully employed. In cases of bleeding, this preemptive interventional and curative treatment is preferable to partial or total nephrectomy, since it preserves the renal parenchyma and kidney function2 2. Williams JM, Racadio JM, Johnson ND, Donnelly LF, Bissler JJ. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis. 2006;47(1):95–102. doi: http://dx.doi.org/10.1053/j.ajkd.2005.09.028. PubMed PMID: 16377390. https://doi.org/10.1053/j.ajkd.2005.09.0... . Currently, however, the preemptive treatment of choice for tuberous sclerosis-related angiomyolipomas is mTOR inhibitors, not embolization3 3. Bissler JJ, Christopher Kingswood J. Renal manifestation of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):338–47. doi: http://dx.doi.org/10.1002/ajmg.c.31654. PubMed PMID: 30307110. https://doi.org/10.1002/ajmg.c.31654... ,4 4. Li M, Zhou Y, Chen C, Yang T, Zhou S, Chen S, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019;14(1):39. doi: http://dx.doi.org/10.1186/s13023-019-1012-x. PubMed PMID: 30760308. https://doi.org/10.1186/s13023-019-1012-... .
- 22 September 2021
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (2) , 715-723
Kidney complications in 107 Fanconi anemia patients submitted to hematopoietic cell transplantation
Fanconi anemia (FA) is a rare disease characterized by progressive bone marrow failure, cancer predisposition, and multiple systemic malformations, including congenital abnormalities of the kidney and urinary tract (CAKUT). Hematopoietic cell transplantation (HCT), the only potentially curative treatment for the hematological complications of FA, may precipitate acute kidney injury (AKI) and hypertension. We retrospectively investigated 107 FA patients who underwent HCT between 2009 and 2017. We investigated the incidence and risk factors of AKI within 100 days after HCT in a cohort of FA patients, and kidney function and hypertension over 2-year follow-up.The incidence of AKI (mainly stage I) was 18.7%. Patients aged ≥ 11 years at transplantation showed a higher risk of AKI (OR 3.53). The eGFR was 60–90 mL/min/1.73 m2 in 53 (49.5%), 55 (51.4%), 50 (50.5%), 50 (51%), and 46 (59.7%) patients before HCT, at 100 days, 6 months, 1 year, and 2 years. Within the first 100 days after HCT, hypertension was observed in 72% of the patients and was associated with cyclosporine therapy. Most (62.3%) patients had stage 2 hypertension. CAKUT was observed in 33.7% of the patients and was associated with both hypertension (86%) and diminished kidney function but not with AKI. Conlusion: Although AKI, a commonly known HCT complication, was mild in this study, the prevalence of chronic kidney disease (CKD), as well as the high incidence of hypertension, specially associated with CAKUT point out the importance of kidney care in short and long-term follow up of FA patients. What is Known: • Fanconi anemia (FA) is the most frequent inherited bone marrow failure in children, and 30% of cases have congenital anomalies of kidney (CAKUT). • Acute kidney injury and hypertension after hematopoietic cell transplantation (HCT) may impact the outcomes.. What is New: • Despite the presence of CAKUT and stage 2 CKD in 33.7% and 50% of the patients, respectively, AKI was mild and transitory after HCT in FA patients. • CAKUT in FA patients was associated with lower kidney function and hypertension after HCT.
- 22 September 2021
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (2) , 715-723
Kidney complications in 107 Fanconi anemia patients submitted to hematopoietic cell transplantation
Fanconi anemia (FA) is a rare disease characterized by progressive bone marrow failure, cancer predisposition, and multiple systemic malformations, including congenital abnormalities of the kidney and urinary tract (CAKUT). Hematopoietic cell transplantation (HCT), the only potentially curative treatment for the hematological complications of FA, may precipitate acute kidney injury (AKI) and hypertension. We retrospectively investigated 107 FA patients who underwent HCT between 2009 and 2017. We investigated the incidence and risk factors of AKI within 100 days after HCT in a cohort of FA patients, and kidney function and hypertension over 2-year follow-up.The incidence of AKI (mainly stage I) was 18.7%. Patients aged ≥ 11 years at transplantation showed a higher risk of AKI (OR 3.53). The eGFR was 60–90 mL/min/1.73 m2 in 53 (49.5%), 55 (51.4%), 50 (50.5%), 50 (51%), and 46 (59.7%) patients before HCT, at 100 days, 6 months, 1 year, and 2 years. Within the first 100 days after HCT, hypertension was observed in 72% of the patients and was associated with cyclosporine therapy. Most (62.3%) patients had stage 2 hypertension. CAKUT was observed in 33.7% of the patients and was associated with both hypertension (86%) and diminished kidney function but not with AKI. Conlusion: Although AKI, a commonly known HCT complication, was mild in this study, the prevalence of chronic kidney disease (CKD), as well as the high incidence of hypertension, specially associated with CAKUT point out the importance of kidney care in short and long-term follow up of FA patients. What is Known: • Fanconi anemia (FA) is the most frequent inherited bone marrow failure in children, and 30% of cases have congenital anomalies of kidney (CAKUT). • Acute kidney injury and hypertension after hematopoietic cell transplantation (HCT) may impact the outcomes.. What is New: • Despite the presence of CAKUT and stage 2 CKD in 33.7% and 50% of the patients, respectively, AKI was mild and transitory after HCT in FA patients. • CAKUT in FA patients was associated with lower kidney function and hypertension after HCT.
- Open Access
- 1 June 2020
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 42 (2) , 219-230
Rare inherited kidney diseases: an evolving field in Nephrology
There are more than 150 different rare genetic kidney diseases. They can be classified according to diagnostic findings as (i) disorders of growth and structure, (ii) glomerular diseases, (iii) tubular, and (iv) metabolic diseases. In recent years, there has been a shift of paradigm in this field. Molecular testing has become more accessible, our understanding of the underlying pathophysiologic mechanisms of these diseases has evolved, and new therapeutic strategies have become more available. Therefore, the role of nephrologists has progressively shifted from a mere spectator to an active player, part of a multidisciplinary team in the diagnosis and treatment of these disorders. This article provides an overview of the recent advances in rare hereditary kidney disorders by discussing the genetic aspects, clinical manifestations, diagnostic, and therapeutic approaches of some of these disorders, named familial focal and segmental glomerulosclerosis, tuberous sclerosis complex, Fabry nephropathy, and MYH-9 related disorder.
- 1 June 2020
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 42 (2) , 219-230
Open AccessRare inherited kidney diseases: an evolving field in Nephrology
There are more than 150 different rare genetic kidney diseases. They can be classified according to diagnostic findings as (i) disorders of growth and structure, (ii) glomerular diseases, (iii) tubular, and (iv) metabolic diseases. In recent years, there has been a shift of paradigm in this field. Molecular testing has become more accessible, our understanding of the underlying pathophysiologic mechanisms of these diseases has evolved, and new therapeutic strategies have become more available. Therefore, the role of nephrologists has progressively shifted from a mere spectator to an active player, part of a multidisciplinary team in the diagnosis and treatment of these disorders. This article provides an overview of the recent advances in rare hereditary kidney disorders by discussing the genetic aspects, clinical manifestations, diagnostic, and therapeutic approaches of some of these disorders, named familial focal and segmental glomerulosclerosis, tuberous sclerosis complex, Fabry nephropathy, and MYH-9 related disorder.